Similarly to the JAVELIN Renal 101 trial results [17], the benefit of pembrolizumab plus axitinib was observed in both PD-L1 expression subgroups (<1 and ≥1) and defined according to the combined positive score (defined as the number of PD-L1–positive cells, such as tumor cells, lymphocytes, and macrophages, divided by the total number of tumor cells, multiplied by 100) [18]. Here, CD274 is linked to neoplasm.